source
- Molecular residual disease testing offers earlier insight into cancer treatment responseIn oncology, determining whether cancer has truly been eliminated after therapy is challenging because imaging and standard clinical criteria often miss low‑level disease. Molecular residual diseas…
- New FDA Oncology Center chief Angelo de Claro pledges AI integration and trial expansionAngelo de Claro, M.D., has taken over as the permanent head of the FDA’s Oncology Center of Excellence after serving as acting director since late 2025. In his first interview, he said the agency w…